| Item | Provisional structured report (seed-only, uncited) |
|---|---|
| Retrieval status / scope | Literature retrieval in this session returned **zero citable contexts**, so this report is **provisional**, **seed-only**, and **cannot prioritize 2023–2024 sources**. Manual verification should use the seed PubMed records: PMID:25062452 — https://pubmed.ncbi.nlm.nih.gov/25062452/ ; PMID:32402064 — https://pubmed.ncbi.nlm.nih.gov/32402064/ ; PMID:34718620 — https://pubmed.ncbi.nlm.nih.gov/34718620/ ; PMID:35718780 — https://pubmed.ncbi.nlm.nih.gov/35718780/ |
| 1. Executive judgment | **Partially supported (provisional).** The seed evidence is consistent with biallelic or otherwise damaging **SYCE1** variants causing meiotic failure via synaptonemal-complex dysfunction, but confidence is limited because the underlying papers were not retrievable for direct verification in this run. |
| 2. Evidence matrix | **PMID:25062452** — human familial genetics: homozygous nonsense SYCE1 variant reported in affected sisters with POI/primary amenorrhea. **PMID:32402064** — model evidence: no detectable SYCE1 protein and markedly reduced transcript, interpreted as infertility through defective homologous chromosome synapsis. **PMID:34718620** — in vitro/human cohort: SYCE1 variants reported to disrupt interaction with **SYCP1** and/or **C14ORF39/SIX6OS1**, affecting SC assembly and meiosis. **PMID:35718780** — human male infertility: SYCE1 CNVs reported in NOA with pachytene-stage arrest on H&E/IF. |
| 3. Clinical spectrum summary | **46,XX:** primary ovarian insufficiency / primary amenorrhea. **46,XY:** non-obstructive azoospermia with reported pachytene-stage spermatogenic arrest. Seed snippets support testis histology/IF evidence for pachytene arrest, but detailed endocrine data (e.g., FSH/AMH), ovarian imaging, follicle depletion, semen parameters, and full biopsy marker panels were not retrievable here. |
| 4. Variant and inheritance summary | Provisional inheritance model: **autosomal recessive / biallelic**. Seed evidence mentions a **homozygous nonsense variant c.613C>T**, additional damaging variants affecting SYCE1 interactions, and **SYCE1 CNVs** in NOA. Exact zygosity/phasing, family counts, CNV breakpoints, segregation details, and ACMG/ClinVar classifications require manual verification from the seed papers. |
| 5. Mechanistic causal chain | Provisional chain: **biallelic SYCE1 loss/damaging variant → reduced or absent SYCE1 → disrupted interaction with SYCP1 and/or C14ORF39/SIX6OS1 → synaptonemal-complex central element assembly failure → homologous chromosome synapsis failure during meiotic prophase I → pachytene arrest/checkpoint activation → germ-cell depletion → 46,XX POI/primary amenorrhea or 46,XY NOA/spermatogenic arrest**. Human support appears strongest for phenotype and arrest endpoints; several intermediate steps likely rely on model or in vitro evidence. |
| 6. Diagnostics and management implications | Provisional practice implications: include **SYCE1** on infertility/POI/NOA genetic testing panels with **CNV detection**; in 46,XY consider semen analysis, endocrine evaluation, and biopsy when clinically indicated; in 46,XX assess ovarian reserve and POI biochemistry. Management likely follows standard care pathways: hormone replacement for POI as indicated, fertility counseling, donor-oocyte discussion for POI, and cautious consideration of micro-TESE/ICSI in NOA if any sperm retrieval is feasible. |
| 7. Ontology suggestions by label only | **HPO:** Primary ovarian insufficiency; Primary amenorrhea; Female infertility; Azoospermia; Non-obstructive azoospermia; Spermatogenic arrest; Hypergonadotropic hypogonadism. **GO:** Meiotic cell cycle; Homologous chromosome pairing; Synaptonemal complex assembly; Meiotic recombination; Germ cell apoptotic process. **CL:** Primary oocyte; Spermatocyte; Pachytene spermatocyte; Germ cell. **Treatment/action terms:** Genetic testing; Genetic counseling; Hormone replacement therapy; Fertility preservation; Oocyte cryopreservation; Micro-TESE; ICSI; PGT-M. |
| 8. Knowledge gaps and weak claims | Major gaps reflect the retrieval block: no full-text verification, no figure/table access, no confirmed hormone values or detailed histology, uncertain CNV zygosity/phasing, and limited ability to distinguish direct human evidence from mouse or in vitro inference. Direct evidence for checkpoint activation or apoptosis in human tissue remains especially uncertain. |
| 9. Curation leads (require curator verification) | After direct review of the seed PMIDs, consider updating the entry to note: (1) a core mechanism of **meiotic synaptonemal-complex central element assembly defect**; (2) dual-sex phenotype of **46,XX POI/primary amenorrhea** and **46,XY NOA/pachytene arrest**; (3) support for **loss-of-function and CNV** mechanisms; and (4) a partner-interaction mechanism involving **SYCP1** and **C14ORF39/SIX6OS1**. Recommended current status for ticketing: **provisional / partially supported pending full-text verification**. |


*Table: This table provides a seed-only provisional summary of the SYCE1-related gametogenic failure mechanism hypothesis, organized by the nine requested output sections. It is useful as a curation-ready placeholder when literature retrieval returns no citable contexts and manual verification of the seed PMIDs is still required.*